Abstract
Objective: We attempted to clarify diagnostic value of combined detection of NLR and serum CRP for migraine patients in attack stage.
Methods: A total of 50 migraine patients in attack stage undergoing treatment in our hospital from June 2023 to June 2024 were chosen as observation group. Additionally, 50 healthy people undergoing physical examination in our hospital were chosen as control group. We adopted questionnaires to obtain the demography, medical history and disease situation of patients in detail. The patients and health examinees received blood routine examination in case of no medication within 3 h after admission. The absolute values of neutrophil (N) and lymphocyte (L) were obtained, followed by calculation of NLR. The serum CRP level received measurement through immune nephelometry. The diagnostic value of NLR and serum CRP for migraine received analysis through receiver operating characteristic curve (ROC).
Results: the serum CRP and NLR levels were significantly higher in the observation group compared with the control group, (P < 0.05).in the observation group, serum CRP and NLR levels in patients with migraine with aura were basically comparable to those in patients without migraine with aura, with no significant difference (P>0.05). Meanwhile, the differences in serum CPP and NLR levels between patients with frequent migraine attacks and patients with infrequent migraine attacks were not statistically significant (P>0.05) Serum CRP or NLR could be utilized for diagnosing migraine patients in attack stage, and diagnosis of migraine through serum CRP or NLR alone presented no difference (P = 0.633). There was statistical significance between combined detection and serum CRP or NLR alone.
Conclusion: Inflammatory biomarkers serum CRP and NLR presented a marked elevation in migraine patients in attack stage. The combination of serum CRP and NLR in diagnosing migraine attack has certain diagnostic value.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.